Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium cantharidate with or without docetaxel versus docetaxel alone as second-line treatment for advanced squamous lung cancer
ChiCTR-IPR-16009159Phase 4Recruiting
- Sponsor
- The Second Xiangya Hospital
- Start
- Sep 2016
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of sodium cantharidate and docetaxel in Pulmonary squamous cell carcinoma (3 arms), sponsored by The Second Xiangya Hospital. Primary endpoint: Progression-free survival. Started Sep 2016; status: recruiting.
02
Drugs
sodium cantharidatedocetaxel
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on ChiCTR-IPR-16009159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-16009159.